On October 17, Fosun Pharma announced a capital increase for its holding subsidiary, Fosun Kite Biotechnology Co., Ltd. The Shenzhen Biomedical Industry Fund (Fosun Health Capital) plans to participate in the Series A financing of Fosun Kite Biotechnology Co., Ltd. (formerly Fosun Kite), intending to contribute a total of 600 million yuan in installments to subscribe for no more than 524,437,452 yuan of new capital.Registered Capital. The current directors and core management team of Fosun Kite, among 14 co-investment participants, plan to collectively contribute 3.525 million yuan through the co-investment platform to subscribe for a total of 3.08107 million yuan of new registered capital in Fosun Kite. The pre-money valuation of this co-investment (Fosun KitePre-investment valuation of 2.2 billion yuan) and this capital increaseProceeds from the Series A financing will be used for the operation and business development of Fosun Kite and/or its subsidiaries.
Shenzhen Biomedical Industry Fund (Fosun Health Capital) on this capital increaseThe delivery of each phase requires the fulfillment of agreed preconditions, including but not limited to the achievement of specified R&D and registration milestones for relevant cell therapy product pipelines. Key milestones include Fosun Kite Biotechnology Co., Ltd. establishing a wholly-owned subsidiary in Shenzhen, the Yikaifa integrated factory reaching the agreed progress, and the agreed equity restructuring plan.Approved by the shareholders' meeting of Fosun Kite, including achieving corresponding clinical and registration progress for the agreed cell therapy product pipeline, completing the agreed equity restructuring, and reaching any of the third-phase investment milestone events (i.e., achieving corresponding registration or commercialization progress for the agreed cell therapy product pipeline, or Fosun Kite reaching the agreed operational targets).
This YearIn September, Fosun KiteThe Second CAR-T Product: Brexucabtagene Autoleucel Injection(FKC889) The drug registration application was accepted by the National Medical Products Administration (NMPA). The indication for this submission isAdult patients with relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL).In September 2024, Kite exited Fosun Kite, selling its 50% equity stake to Fosun Pharma Industry for US$27 million. October 2024Fosun KiteRenamed to Fosun Kite.Before and after the completion of this capital increase and this follow-up investment, the changes in the equity structure of Fosun Kite are as follows:Pingshan District Guidance Fund signed an investment agreement with Fosun Kite on September 15, 2025. The Pingshan District Guidance Fund plans to invest 50 million yuan to participate in Fosun Kite.Series A financing. As of the date of this announcement, the industrial and commercial change registration for this capital increase is still pending.In 2024, Fosun Kite achieved operating revenue of 32,834.RMB 100 million, net profit -RMB 337.18 million. Revenue mainly came from the commercialization of the first CAR-T cell therapy product, Yikai Da (Axicabtagene Ciloleucel Injection). As of June 30, 2025, Fosun Kite Biotechnology Co., Ltd.'s total assets amounted to RMB 833.44 million, owner's equity was RMB 136.84 million, and total liabilities were RMB 696.59 million. From January to June 2025, Fosun Kite achieved operating revenue of RMB 220.19 million and a net profit of -RMB 160.93 million.Follow the official account below to see the world!
